Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04367883 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Publications revised (6)v10
  2. Study completion date: May 31, 2025 to Feb 24, 2028v9
  3. Primary completion date: Sep 30, 2024 to Jan 19, 2025
    • Study completion date: Dec 31, 2024 to May 31, 2025
    • Publications: 4 to 6
    v8
  4. Primary completion date: Sep 30, 2023 to Sep 30, 2024
    • Study completion date: Dec 31, 2023 to Dec 31, 2024
    v7
  5. Primary completion date: Sep 30, 2022 to Sep 30, 2023v6 Show 9 more changesShow less
    • Enrollment target: 2574 to 3000
    • Study completion date: Aug 31, 2023 to Dec 31, 2023
    • Interventions: ACE inhibitor (Drug), ARB (Drug) to ACEI (Drug), ARB (Drug), Amantadine (Drug), Antihistamine (Drug), Influenza vaccine and COVID (Other)
    • Eligibility criteria revised
    • Secondary endpoints: details revised at 1 of 1 entry
    • Publications: 2 to 4
    • Study title revised
    • Study arms: 1 to 3
    • Study description expanded, about 5 words
Show 4 earlier versionsHide 4 earlier versions
  1. Re-verified, no change to tracked fieldsv5
  2. Primary completion date: Sep 30, 2020 to Sep 30, 2022v4
  3. Eligibility criteria expanded, about 30 wordsv3
  4. Primary completion date: Jul 30, 2020 to Sep 30, 2020
    • Secondary endpoint revised
    • Study description expanded, about 80 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection. Other authors described how none of the elderly patients receiving antihistamines and azythromycin in two nursing homes in Toledo -Spain- during the first wave died or needed hospital admission, even considering that 100% of residents had a positive serological test after that wave. Other authors have described a positive evolution in patients receiving amantadine for their Parkinson's disease. The aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving these treatments showed a better evolution.
Trial Details
NCT Number NCT04367883
Lead Sponsor Consorci Sanitari de Terrassa
Collaborators: Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina, Institut Català de la Salut
Conditions
(from sponsor)		 COVID19, Influenza Vaccination, ACE Inhibitors, ARB, Antihistamine Allergy, Amantadine
Related terms COVID-19, Influenza, Human
Enrollment 3,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov